Grifols A : Biotest acquisition: a deal with high synergies and a good rationale
>A deal with high strategic fit - Grifols explained during a presentation to analysts the main reasons for the Biotest acquisition: 1) Improve Grifols' position in the plasma-derived business by accelerating and expanding its commercial pipeline. Biotest will provide a more balanced global footprint, increasing Grifols' operations and revenues in Europe, the Middle East and Africa; 2) Bring innovative therapies to drive revenue growth and expansion. Biotest is develop...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.